.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Colorcon
UBS
Teva
Express Scripts
Moodys
McKesson
Accenture
Chinese Patent Office
Daiichi Sankyo

Generated: July 26, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Method for treatment of gastro intestinal disorders
Abstract:A method is disclosed for preventing recurrence of duodenal ulcer associated with Campylobacter pylori infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound; a first antibiotic selected from the group consisting of tetracycline and penicillins and second antibiotic which is metronidazole.
Inventor(s): Borody; Thomas J. (Five Dock, AU)
Assignee:
Application Number:07/466,310
Patent Claims: 1. A method of preventing recurrence of duodenal ulcer associated with Campylobacter pylori infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection, said method comprising administering to said patient Campylobacter pylori infection eradicating amounts of pharmaceutically acceptable bismuth compound, first antibiotic selected from the group consisting of tetracycline and penicillins and second antibiotic which is metronidazole.

2. The method of claim 1 wherein said administering is to cause healing of duodenal ulcer as well as to prevent recurrence thereof.

3. A method of treating a patient with duodenal ulcer associated with Campylobacter pylori infection, said method comprising administering to said patient acid suppressant in an amount effective to obtain symptomatic relief and ulcer epithelialization before or during administering to said patient of Campylobacter pylori infection eradicating amounts of pharmaceutically acceptable bismuth compound, first antibiotic selected from the group consisting of tetracycline and penicillins and second antibiotic which is metronidazole, thereby to cause healing of said duodenal ulcer as well as to prevent recurrence thereof. s
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Medtronic
Farmers Insurance
Colorcon
Express Scripts
Cantor Fitzgerald
UBS
Moodys
Merck
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot